We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.9B
1-Year Est. Return 121.13%
This Fund
S&P 500
This Quarter Est. Return
+3.15%
1 Year Est. Return
+121.13%
3 Year Est. Return
+281.43%
5 Year Est. Return
+350.91%
10 Year Est. Return
–
AUM
$1.57B
AUM Growth
+$120M
Cap. Flow
+$109M
Cap. Flow %
6.95%
Top 10 Hldgs %
44.48%
Holding
133
New
28
Increased
33
Reduced
33
Closed
26

Top Buys

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$40.1M
2
CLDX icon
Celldex Therapeutics
CLDX
+$25.8M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$21.7M
4
HQY icon
HealthEquity
HQY
+$12.8M
5
ARKK icon
ARK Innovation ETF
ARKK
+$9.18M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$60.1M
2
BMY icon
Bristol-Myers Squibb
BMY
+$27.8M
3
CTLT
CATALENT, INC.
CTLT
+$24.5M
4
LH icon
Labcorp
LH
+$23.9M
5
MASI
Masimo
MASI
+$18.1M

Sector Composition

Rank Sector Weight
1 Healthcare 72.04%
2 Industrials 1.19%
3 Technology 0.06%
4 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GRTS
76
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$2.19M 0.14%
+170,125
New +$1.88M
MRTX
77
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.18M 0.14%
14,840
+5,485
+59% +$852K
KRTX
78
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$2.09M 0.13%
15,934
-9,066
-36% -$1.17M
AUTL
79
Autolus Therapeutics
AUTL
$386M
$2.08M 0.13%
401,540
+3,466
+0.9% +$20.8K
ACAD icon
80
CALL
Acadia Pharmaceuticals
ACAD
$4.25B
$1.97M 0.13%
84,600
– –
SNY icon
81
Sanofi
SNY
$104B
$1.94M 0.12%
38,672
-220,456
-85% -$10.9M
ESTA icon
82
Establishment Labs
ESTA
$2.72B
$1.7M 0.11%
+25,137
New +$1.76M
UTHR icon
83
CALL
United Therapeutics
UTHR
$26.3B
$1.64M 0.1%
+7,600
New +$1.49M
SRGA
84
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$1.37M 0.09%
63,958
-52,993
-45% -$1.42M
ADAP
85
DELISTED
Adaptimmune Therapeutics
ADAP
$1.31M 0.08%
348,716
-96,171
-22% -$438K
RGEN icon
86
Repligen
RGEN
$7.44B
$1.21M 0.08%
4,584
+182
+4% +$49K
TECX
87
Tectonic Therapeutic
TECX
$573M
$1.17M 0.08%
25,416
-4,541
-15% -$261K
MYO icon
88
Myomo
MYO
$37.5M
$1.03M 0.07%
150,000
– –
VCRA
89
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$971K 0.06%
+14,970
New +$842K
MIST icon
90
Milestone Pharmaceuticals
MIST
$144M
$964K 0.06%
147,165
+33,568
+30% +$201K
ENSG icon
91
The Ensign Group
ENSG
$10.1B
$874K 0.06%
10,397
– –
HSKA
92
DELISTED
Heska Corp
HSKA
$826K 0.05%
4,525
– –
ACIU icon
93
AC Immune
ACIU
$227M
$759K 0.05%
153,380
-68,369
-31% -$397K
ASMB icon
94
Assembly Biosciences
ASMB
$506M
$722K 0.05%
25,833
-3,334
-11% -$109K
LOGC
95
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$672K 0.04%
291,101
-58,818
-17% -$199K
CYCN icon
96
Cyclerion Therapeutics
CYCN
$15.2M
$640K 0.04%
18,598
– –
MRUS
97
DELISTED
Merus
MRUS
$604K 0.04%
+19,000
New +$537K
ORTX
98
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$554K 0.04%
41,958
-15,000
-26% -$248K
ELDN icon
99
Eledon Pharmaceuticals
ELDN
$276M
$503K 0.03%
114,008
– –
GOSS icon
100
Gossamer Bio
GOSS
$66.5M
$451K 0.03%
39,910
-110,000
-73% -$1.31M
2 3
4
5 6

Similar funds

DCP
Distillate Capital Partners Chicago, Illinois $1.9B AUM 2.22% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $1.89B AUM 14.55% 1-Year Est. Return
OPCM
Osborne Partners Capital Management San Francisco, California $1.89B AUM 16.21% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
RCA
Resonant Capital Advisors Madison, Wisconsin $1.9B AUM 14.38% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $1.91B AUM 24.91% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
TF
Trek Financial Scottsdale, Arizona $1.88B AUM 41.21% 1-Year Est. Return

Eversept Partners's Q4 2021 Portfolio in Review

As of Q4 2021, Eversept Partners held 133 positions worth $1.57B, up 8.3% from $1.45B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Eversept Partners deployed $109M of net new capital in Q4 2021, opening 28 new positions and adding to 33 existing holdings. Its largest new stake was Biohaven Pharmaceutical Holding Company Ltd.: 315,129 shares worth $43.4M.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, down from 80% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Labcorp, an estimated $23.9M trimmed.

  • Eversept Partners's largest Q4 2021 buy was Biohaven Pharmaceutical Holding Company Ltd.: 315,129 shares worth $43.4M.
  • Eversept Partners added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2021, an estimated $21.7M increase.
  • Eversept Partners's biggest Q4 2021 reduction was Labcorp, cutting an estimated $23.9M.
  • Eversept Partners fully exited Acceleron Pharma in Q4 2021, selling an estimated $60.1M.
  • Eversept Partners's ten largest holdings make up 44% of its $1.57B portfolio in Q4 2021.
  • Eversept Partners opened 28 new positions and closed 26 in Q4 2021.
  • Eversept Partners's portfolio value rose 8.3% quarter-over-quarter to $1.57B.

Based on Eversept Partners's 13F filing for Q4 2021, filed 14 Feb 2022.